GlassScriptPhysician profile
Jacqueline Darcey
NPI 1376515593
$3,595.00
in general payments reported to CMS, 2019-2025
35 companies · $771 in 2025
The $771 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $167 · 2021: $160 · 2022: $194 · 2023: $505 · 2024: $1,345 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $630.06 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $538.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $186.56 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $178.79 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $174.40 | 2019-2024 | |
| Glaxosmithkline, LLC. | $171.04 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $158.26 | 2019-2021 | |
| Allergan, INC. | $127.70 | 2019 | |
| Exact Sciences Corporation | $103.05 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $96.92 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $92.70 | 2023-2025 | Rexulti, Nuedexta |
| Abbott Laboratories | $88.76 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $85.99 | 2019-2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $84.99 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $79.18 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $74.79 | 2024-2025 | |
| Corcept Therapeutics | $66.76 | 2024 | Korlym |
| Abbvie INC. | $62.99 | 2021-2024 | Ubrelvy |
| Tandem Diabetes Care, INC. | $60.77 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $56.06 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $54.80 | 2022-2024 | |
| Corium, LLC | $52.74 | 2022-2023 | Adlarity |
| Dexcom, INC. | $43.54 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $42.92 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $39.14 | 2019 | |
| Xeris Pharmaceuticals, INC. | $38.18 | 2021-2024 | Gvoke Hypopen |
| Ani Pharmaceuticals, INC. | $37.17 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.68 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $27.95 | 2021 | |
| Avanir Pharmaceuticals, INC. | $27.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2025 | Trintellix |
| Irhythm Technologies, INC. | $15.51 | 2022 | |
| Sumitomo Pharma America, INC. | $14.97 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2024 | Zoryve |
| Ucb, INC. | $13.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Darcey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.